Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Fulgent Genetics, Inc. (FLGT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619.0M | $992.6M | $421.7M | $32.5M | $21.4M | $18.7M | $18.3M | $9.6M | $1.3M |
| Gross profit | $130.9M | $107.2M | $104.5M | $366.9M | $777.1M | $331.9M | $18.4M | $10.7M | $10.2M | $11.6M | $4.5M | $342,000 |
| Research & development | $53.9M | $48.8M | $41.4M | $28.9M | $24.2M | $11.6M | $6.5M | $5.5M | $4.2M | $3.6M | $4.4M | $521,000 |
| Operating expenses | $222.0M | $181.1M | $300.0M | $188.4M | $101.1M | $41.7M | $18.8M | $15.7M | $13.7M | $10.6M | $9.5M | $1.3M |
| Operating income | −$91.1M | −$73.9M | −$195.5M | $178.5M | $676.0M | $290.2M | −$428,000 | −$5.1M | −$3.5M | $918,000 | −$5.0M | −$990,000 |
| EBITDAderived | −$67.0M | −$49.0M | −$169.4M | $211.2M | $687.0M | $293.1M | $1.7M | — | −$1.8M | $2.1M | −$4.4M | −$794,000 |
| Net income | −$60.5M | −$42.7M | −$167.8M | $143.4M | $507.4M | $214.3M | −$411,000 | −$5.6M | −$2.5M | −$5.3M | −$8.3M | −$4.3M |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 2, 2026Form 4 | Xie JianPresident and COO | SellCommon Stock | 2.1K | $17.89 | $38.4K | 367.6K |
| Jun 2, 2026Form 4 | Gao HanlinChief Scientific Officer | SellCommon Stock | 1.7K | $17.89 | $30.2K | 990.4K |
| May 27, 2026Form 4 | Xie JianPresident and COO | SellCommon Stock | 1.2K | $17.60 | $21.1K | 369.8K |
| May 27, 2026Form 4 | Gao HanlinChief Scientific Officer | SellCommon Stock | 945 | $17.60 | $16.6K | 992.1K |
| Dec 2, 2025Form 4 | Xie JianPresident and COO | SellCommon Stock | 1.1K | $28.33 | $32.3K | 336.7K |